Home > Insider Trading > Filing (0001209191-21-008935)

Filing Details

Accession Number:: 0001209191-21-008935
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-09 18:14:02
Reporting Period:: 2021-02-05

Accepted Time:: 2021-02-09 18:14:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1708493	Harpoon Therapeutics Inc.	HARP	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1134655	Ansbert Gadicke	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1134657	Luke Evnin	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1263048	Mpm Asset Management Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1473930	Todd Foley	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1609492	Mpm Bioventures 2014, L.p.	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1609493	Mpm Bioventures 2014 (B), L.p.	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1609495	Mpm Asset Management Investors Bv2014 Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1765021	Mpm Bioventures 2014 Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1765091	Mpm Bioventures 2014 Gp Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-02-05	10,172	$20.01	3,502,885	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-02-08	72,128	$20.04	3,430,757	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-02-09	9,400	$20.25	3,421,357	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,898,422	Indirect	See Footnote

Footnotes

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 12/21/2020.
The shares were sold as follows: 9,816 by MPM BioVentures 2014, L.P. ("BV 2014") and 356 by MPM Asset Management Investors BV2014 LLC ("AM BV2014").
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.96 to $20.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,922,355 by BV 2014, 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 105,997 by AM BV2014 and 322,063 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Luke Evnin, Ansbert Gadicke and Todd Foley are the members of BV LLC and Luke Evnin and Anbert Gadicke are the members of AM LLC.
Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were sold as follows: 69,604 by BV 2014 and 2,524 by AM BV2014.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,852,751 by BV 2014, 152,470 by BV 2014(B), 103,473 by AM BV2014 and 322,063 by AM LLC. MPM BioVentures 2014 GP LLC and BV LLC are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Luke Evnin, Ansbert Gadicke and Todd Foley are the members of BV LLC and Luke Evnin and Anbert Gadicke are the members of AM LLC.
The shares were sold as follows: 9,071 by BV 2014 and 329 by AM BV2014.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,843,680 by BV 2014, 152,470 by BV 2014(B), 103,144 by AM BV2014 and 322,063 by AM LLC. MPM BioVentures 2014 GP LLC and BV LLC are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Luke Evnin, Ansbert Gadicke and Todd Foley are the members of BV LLC and Luke Evnin and Anbert Gadicke are the members of AM LLC.
The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the Managing Member of Oncology GP LLC.